233 results about "Glucuronate" patented technology

The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+/-0.3):(1+/-0.3):(3.5+/-0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and/or treating thrombotic diseases.

The invention provides a method for oriented biosynthesis of GAMG, and belongs to the technical fields of biosynthesis and biotransformation. The method comprises the following steps: producing corresponding beta-D-glucuronidase by penicillium purpurogenum stoll in a fermentation medium; adding the obtained beta-D-glucuronidase into conversion solution containing glycyrrhizic acid substrate, orientedly hydrolyzing the glycyrrhizic acid under the action of enzyme, and obtaining a coarse product of GAMG; and performing organic solvent extraction, resin adsorption and purification to obtain a GAMG product. The method takes microbialenzyme as a catalyst, and has high reaction efficiency, no pollution, simple steps, and low cost; and the product is single and has high purity.

The invention discloses an ursolic acid-3-O-beta-D-pyranglucuronide and pharmaceutically acceptable salts or esters thereof, and a preparation method and a medicinal application of a compound, and especially an application in preparing medicaments for resisting diabetes and complications thereof. The ursolic acid-3-O-beta-D-pyranglucuronide and pharmaceutically acceptable salts or esters thereof have obvious function of reducing blood sugar, and especially have favorable efficacy of reducing hyperglycemia after meals.

A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferring activity and N-acetylgalactosamine transferring activity.

The invention discloses a chromogenic medium used for detecting esherichia coli O157:H7. The medium comprises agar, peptone, beef extract powder, sodium chloride, sorbitol, inositol, neutral red, beta-galactosidase chromogenic substrate, beta-glucuronidase chromogenic substrate, isopropyl-beta-D- thiogalactopyranoside, natrium taurocholicum, potassium tellurite and cefixime. The chromogenic medium used for detecting esherichia coli O157:H7 of the present invention has the advantages of high sensitivity, good specificity, direct bacterial strain discrimination according to colony color, short detection period and strong operationality, is suitable for treating high-reflux samples, is capable of comprehensively, systematically and accurately detecting and preliminarily identifying the esherichia coli O157:H7 in food production and environment, and provides a novel approach for rapidly detecting the microbes.

The invention discloses a vaginitis test kit which comprises a reaction device, a sampling test tube, a straw, joint test diluent, joint test chromogenic reagent, joint test stop solution, a user manual and a joint test colourimetric card, wherein a hydrogen peroxide reaction hole, a leukocyte esterase reaction hole, a sialic acid glucoside enzyme reaction hole, a beta- glucuronic acid enzyme reaction hole, a P glucosidase reation hole and a pH value hole; relevant reaction bases are arranged in the reaction holes; reach reaction base comprises a corresponding reaction substrate curing layer,a chromogenic promotional layer and a chemical inert carrier layer. The invention also provides a preparation method of the test kit and the preparation method of a novel chemical carrier. The test kit can be used for distinguishing bacterial vaginosis and vaginitis, and can further identify aerobic/anaerobic bacteria, facultative anaerobic bacteria and other flora in vaginal secretion. The method is simple and quick to operate, has high accuracy, and is applicable to clinical practice, particularly hospital outpatient practice.

The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a β (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH₃ group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18−19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase derma-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.

The invention relates to a coumarin compound acidulated by glucal and application thereof. The compound has a structure showed in the right formular, wherein R is one of-H, -OH, -CH3, -OCH3, -NH2 or ester group; and R1, R2, R3 and R4 are one of -H, -OH, -CH3, -SH, -OCH3, -NH2 or glucal acid group. The coumarin compound acidulated by the glucal has the activities of resisting arthritic and tumor.

This invention relates generally to compounds that are glucuronidase inhibitors. Glucuronidase inhibitors described include phenoxy thiophene sulfonamides. Other compounds, for instance pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls, are also contemplated. Also contemplated are compositions including one or more of such compounds for use inhibiting glucuronidase and methods of using one or more of such compounds as a co-drug to be used in combination with the anticancer drug CPT-11.

The invention discloses a method for preparing scutellarin by using Aspergillus niger AS 3.795 for hydrolyzing scutellarin-7-O-glucuronide. Aspergillus niger AS 3.795 is used for hydrolyzing scutellarin-7-O-glucuronide glucuronyl to prepare the scutellarin. The method comprises the following steps of: using Aspergillus niger AS 3.795 to biologically transform a substrate scutellarin-7-O-glucuronide, using ethyl acetate to extract transformation products from fermentation liquor and using D101 macroporous adsorption resin column chromatography and recrystallization to purify the transformation products. The purity of the prepared transformation products can reach more than 99 percent according to high performance liquid chromatography. The method has the advantages that the defect that glucuronide is difficult to hydrolyze is overcome, the scutellarin can be prepared in a large scale under moderate conditions such as normal temperature and normal pressure, the environmental protection is facilitated, the production cost is reduced and the method is suitable for industrialized production.

The invention provides a Dongxiang wild rice endophytic fungus strain capable of transforming glycyrrhizic acid to produce glycyrrhetinic acid monoglucuronide. The strain is identified and named as Aspergillus flavus DX-SEL2 and preserved in China Center for Type Culture Collection, with an accession number of CCTCC NO: M2013686. The strain can induce generation of beta-glucuronidase in a transformation medium with a glycyrrhizic acid as an inductive agent, then hydrolysis is carried out so as to remove a glucuronyl group at the terminal of a glycyrrhizic acid molecule, so glycyrrhetinic acid monoglucuronide is produced (secreted in fermentation broth). Organic solvent extraction, normal-phase silica gel column chromatography, reversed-phase silica gel column chromatography and the like are used for further separation and purification so as to obtain glycyrrhetinic acid monoglucuronide. According to the invention, microbial catalytic conversion is employed, and the advantages of greenness, environmental protection, no pollution, simple transformation steps, a single product, a high transformation rate, etc. are obtained.

The present invention provides for a crystalline form of trimetrexate either as a glucuronate, acetate, hydrochloride, methanosulfonate or lactate salt, which can be processed galenically as a stable, well-defined solid substance and processes for producing the crystalline forms. Such crystalline forms allow for prolonged stability in storage and for oral and intravenous administration of the drug.

The invention relates to a preparation method and application of a folium apocyni veneti extract, belongs to the field of medicines and aims at increasing the extraction content of quercetin-3-O-beta-D-glucosyl-beta-D-glucoside and quercetin-3-O-beta-D-glucuronide in folium apocyni veneti by 0.5-10 percent and applying the quercetin-3-O-beta-D-glucosyl-beta-D-glucoside and the quercetin-3-O-beta-D-glucuronide to a medicament for treating depression. According to the folium apocyni veneti extract, the total flavonoids content is 58-78 percent, wherein the contained flavonoids component is prepared from the following components in percentage by weight: 5.0-25 percent of the quercetin-3-O-beta-D-glucosyl-beta-D-glucoside, 0.5-10 percent of the quercetin-3-O-beta-D-glucuronide, 0.5-20 percent of rutin, 5.0-25 percent of hyperin, 5.0-20 percent of isoquercetin, 2.0-10 percent of quercetin, 2.0-10 percent of kaempferol and the balance of other flavonoids components. The preparation method and the application are convenient and efficient, are easy in operation and low in cost, can meet development and utilization of the fields of the medicines and foods and have very large application and development values.

The invention discloses a preparation method of apigenin-7-O-beta-D-glucuronide, and a use of of apigenin-7-O-beta-D-glucuronide, and belongs to the fields of extraction and application of effective components of traditional Chinese medicines. The method comprises the steps of extraction, water precipitation and purification. The method is simple and convenient, and the prepared apigenin-7-O-beta-D-glucuronide has a high purity, and has a good curative effect on the coronary heart disease and myocardial infarction.

The invention relates to compound wine and a preparation method thereof. The compound wine comprises sodium hyaluronate, wherein the content of sodium hyaluronate in white spirit per litre is 50-300mg. The compound wine is characterized in that the average relative molecular mass of sodium hyaluronate is 5017-6689 daltons, that is sodium hyaluronate is mucopolysaccharide formed by alternately bonding 10-20 acetylglucosamine and sodium glucuronate disaccharide units. The preparation method of the compound wine employs a hydration-gelation-dissolution staged dissolution technology to allow HA (hyaluronic acid) to be capable of being dissolved in a wine base more uniformly. The compound wine is potable wine comprising new resource food sodium hyaluronate, can keep a style of white spirit, and reaches the GB/T 27588 standard on liqueur which is clear, transparent and free from precipitate and suspended matter, the turbidity is reduced simultaneously, and the long-term stable presence of sodium hyaluronate in the wine base can be ensured.

The invention belongs to the technical field of analytical chemistry, and relates to a method of realizing simultaneous rapid analysis on perfluorinate chemicals, phenolic chemicals and estrogen in blood, so as to solve the defects of expensive analysis, long analysis time and affected analysis efficiency when three different analysis methods are required in current analysis to detect blood and urine of the same research object. After beta-glucuronidase, acid or alkali is adopted to hydrolyze a blood sample, the blood sample is purified by solid phase extraction, the PFCs, the phenolic chemicals and the estrogen in the blood are simultaneously detected by using liquid chromatography tandem mass spectrometry, and the analysis results show that through one-time sample pretreatment and chromatographic analysis, the PFCs, the phenolic chemicals and the estrogen in the blood are analyzed simultaneously, the defects of simultaneously analyzing the three kinds of chemicals currently can be obviously solved, and the analysis efficiency is improved.

The present application relates to a salt of a pyranose-substituted heterocyclic compound, a preparation method therefor, and use thereof, and in particular, to an acid addition salt of a compound of formula (I) or a prodrug thereof, and further relates to D-glucuronate of a crystalline compound of formula (I) or a prodrug thereof. D-glucuronate of a crystalline compound of formula (II) has particular advantages in terms of crystallizability, subsequent purification, stability, formulation medicinal properties or quality control, and is most applicable for improving the formulation pharmaceutical properties, purity and quality control, as well as large-scale process development of such drugs.

The present invention relates to a multi portion intra-oral dosage form comprising at least one pharmaceutically active agent or health promoting agent wherein at least one portion comprises a component for creating a noticeable organoleptic sensation. Of certain interest is use of sensory markers/signals as conceptual aids for a subject using the dosage form whereby the organoleptic sensation/s is/are such that it/they facilitate/s for the subject to identify a portion and differentiate between different portions thereof. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and/or metabolites thereof, such as cotinine, nicotine N'-oxide, nornicotine, (S)-nicotine-N--glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms.

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.

The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.

The invention relates to a method for rapidly detecting steroid hormones in urea through an UPLC-MS/MS technology, and belongs to the field of analysis chemistry and medical science. The concentrations of estriol, hydrocortisone, 17beta-estradiol, testosterone and progesterone in human urea are simultaneously detected through the UPLC-MS/MS technology by adopting a beta-glucuronidase enzymatic hydrolysis technology, the detection limit is 0.1-1.0 ng/mL, and the quantitation limit is 0.3-3.0 ng/mL. The method is fast, sensitive and accurate, can meet requirement of simultaneous detection of above five steroid hormones in urea, and has wide application prospect.

Provided are a method for producing a fraction containing more than 50% of CH represented by the general formula (1), which comprises at least the step of allowing a glucuronic acid donor, an N-acetylgalactosamine donor, a saccharide receptor, a chondroitin polymerase derived from the Escherichia coli K4 strain, and Mn²⁺ at a final concentration of 0.02 to 100 mM to coexist, and performing a reaction thereof under conditions of 20 to 40° C. and pH 6 to 8 for 0.5 minutes to 4 hours, and a method for producing a fraction containing more than 50% of CH represented by the general formula (2), which comprises at least the step of performing the reaction under same conditions for 10 hours or longer, which enable industrial scale production of a CH fraction of a controlled even number saccharide and odd number saccharide content ratio by a simple procedure at a low cost.

(GlcA-GalNAc)_n   (1)

GalNAc-(GlcA-GalNAc)_n   (2)

• (In the formula, GlcA represents a glucuronic acid residue, GalNAc represents a N-acetylgalactosamine residue, - represents a glycosidic bond, and n represents an arbitrary integer.)